After noticing concerning patient survival data across multiple clinical trials, the FDA is losing confidence in the safety profile of the notoriously toxic PI3K inhibitor drug class for blood cancers ...
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, PI3K Inhibitor pipeline constitutes 20+ key companies continuously working towards developing 25+ PI3K Inhibitor ...
Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas. While multimodal therapies have improved outcomes for low- and intermediate-risk ...
Novartis published trial results showing its drug succeeded in tackling difficult to treat breast cancer with PIK3CA mutation, after other pharma giants including Roche failed and abandoned similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback